Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

EMA accepts Otsuka and Astex’s marketing authorisation application for acute myeloid leukaemia treatment 

The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

- PMLiVE

Pfizer and BioNTech seek FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies have rapidly increased production of the newly developed vaccine and are ready to deliver doses from September

EU flag

EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin

Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%

- PMLiVE

Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment

More than 4.9 million people in the UK have diabetes, around 90% of which have type 2 diabetes

- PMLiVE

Moderna to supply Canada with 12 million doses of Omicron-containing bivalent COVID-19 booster

The company announced in July that it was advancing two bivalent candidates for autumn, based on different population health security strategies in different countries

- PMLiVE

Medscape: At the Heart of Education at #ESCCongress

Medscape Education Global will attend ESC from September 26-29 to host live symposia and an in-person event on key topics in cardiology.

Medscape Education

Learning Program Webinar Series & Community Board

A Customer Story

Impetus Digital

The Sofa Sessions – The Third Page

Page & Page Health

FlyPharma Europe unites pharma, biotech and bio pharma with air cargo logistics

In the middle of the pandemic, the pharma industry was under pressure to not just maintain but increase its existing business, while navigating the logistical challenges that COVID-19 placed in...

- PMLiVE

WHO recommends Valneva’s COVID-19 vaccine for those aged between 18 to 50 years old

VLA2001 is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine, employing a similar approach to the flu vaccine

- PMLiVE

EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

The biosimilar to Genentech's Avastin was found to be highly similar to the reference product

- PMLiVE

Pfizer told by FDA to test additional Paxlovid course in patients with COVID-19 rebound

The company must produce the initial results of a randomised controlled trial by 30 September next year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links